Bank of America’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-119,388
| Closed | -$1.79M | – | 7632 |
|
|
2016
Q2 | $1.79M | Buy |
119,388
+100,123
| +520% | +$1.29M | ﹤0.01% | 3715 |
|
|
2016
Q1 | $234K | Sell |
19,265
-17,911
| -48% | -$251K | ﹤0.01% | 5057 |
|
|
2015
Q4 | $591K | Buy |
37,176
+21,776
| +141% | +$343K | ﹤0.01% | 4705 |
|
|
2015
Q3 | $236K | Sell |
15,400
-9,093
| -37% | -$197K | ﹤0.01% | 5244 |
|
|
2015
Q2 | $595K | Buy |
24,493
+14,622
| +148% | +$350K | ﹤0.01% | 4564 |
|
|
2015
Q1 | $230K | Sell |
9,871
-9,597
| -49% | -$254K | ﹤0.01% | 4840 |
|
|
2014
Q4 | $489K | Buy |
19,468
+16,288
| +512% | +$478K | ﹤0.01% | 4640 |
|
|
2014
Q3 | $99K | Buy |
3,180
+182
| +6% | +$4.93K | ﹤0.01% | 6017 |
|
|
2014
Q2 | $78K | Buy |
2,998
+2,000
| +200% | +$44.4K | ﹤0.01% | 6330 |
|
|
2014
Q1 | $23K | Sell |
998
-2,850
| -74% | -$62.3K | ﹤0.01% | 6848 |
|
|
2013
Q4 | $98K | Sell |
3,848
-19,791
| -84% | -$447K | ﹤0.01% | 6145 |
|
|
2013
Q3 | $482K | Buy |
23,639
+10,609
| +81% | +$236K | ﹤0.01% | 4677 |
|
|
2013
Q2 | $273K | Buy |
+13,030
| New | +$233K | ﹤0.01% | 5324 |
|
Bank of America's SGNT Position: Q3 2016 in Review
Bank of America sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 119,388 shares — an estimated $1.79M sold.
Bank of America first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $1.79M in Q2 2016. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Bank of America reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Bank of America sold 119,388 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $1.79M.
- Bank of America first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Bank of America's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $1.79M in Q2 2016.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Bank of America's 13F filing for Q3 2016, filed 14 Nov 2016.